Otsuka Pharmaceutical announced that its anti-APRIL monoclonal antibody, sibeprenlimab (brand name: VOYXACT®), has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with primary IgA nephropathy. As the first therapy selectively targeting APRIL (A Proliferation-Inducing Ligand), sibeprenlimab intervenes in disease progression at its source by blocking a key step in the generation of pathogenic IgA.

The development of this sector has three distinct milestones: from 2019 to 2021, it was in an exploratory phase, with only a few small-sample clinical trials conducted in China; from 2022 to 2024, it entered a critical period for regulatory approval, during which multiple companies advanced their efforts simultaneously, yet no product obtained NMPA registration certification; in 2025,H&H Healthcare's K-Clip received approval, marking the official start of the commercialization era and serving as a turning point for the sector's development.

This collaboration aims to discover candidate drugs with clinical differentiation advantages for high-potential therapeutic targets. By applying advanced generative AI models to the early stages of drug development, both teams are poised to comprehensively enhance the quality of candidate molecule design and conduct structural optimization, striving to achieve best-in-class efficacy and ideal safety profiles.

According to reports, PRIMEAI's artificial intelligence modules can achieve gross margins of 70% to 80%, with overall delivery gross margins exceeding 60%. This high-profitability business model precisely aligns with pharmaceutical companies' demands for cost reduction and efficiency improvement. In 2026, the company is projected to achieve revenue exceeding RMB 100 million, with total contract value approaching RMB 160 million, marking the entry of its commercialization into a phase of exponential growth.

Alebund Pharmaceuticals (Jiangsu) Limited, a clinical-stage biotech focused on chronic kidney disease treatments, made its debut on the Hong Kong Stock Exchange June 29, 2026, with its stock jumping more than 95% to HK$44 at press time and valuing the firm at roughly HK$15 billion. The IPO is set to raise HK$1.181 billion, with 34% earmarked for the New Drug Application filing and global Phase 3 multi-center studies of flagship asset AP301, 37% allocated to global Phase 2b trials for AP306 alongside progress on pipeline candidates including AP308 and AP303, and 12% designated for capacity expansion at its Yangzhou manufacturing facility and pre-launch commercial preparations for future approved therapies.

It forms an effective portfolio strategy with Keppra: Keppra, as a broad-spectrum foundational medication, covers a wide patient population with epilepsy and provides stable cash flow; Vimpat, as a next-generation specialized product, targets more segmented treatment scenarios with higher efficacy demands, representing future growth potential. This "cornerstone product + growth product" combination effectively balances current revenue with future opportunities.

If Abbisko Therapeutics successfully advances the compound to the agreed-upon milestone, Eli Lilly will have the right to further develop and commercialize it, with a corresponding total potential consideration of $258 million. If Eli Lilly chooses not to advance the compound, Abbisko Therapeutics will retain the right to further develop and commercialize it.

The innovative drug industry is fiercely competitive, with a scarcity of high-quality, differentiated late-stage pipelines, forcing MNCs to pivot toward early-stage projects. Although China's innovative drug R&D system is characterized by being "fast, cost-effective, and efficient," this does not alter the fundamental principles of drug development: late-stage projects have a higher likelihood of successful commercialization, whereas early-stage projects suffer from lower success rates.

Peripheral Drug-Coated Balloons (Peripheral DCBs) are core consumables for peripheral arterial interventional therapy, suitable for various scenarios such as lower extremity vascular stenosis, in-stent restenosis, and arteriovenous fistula lesions. Compared with traditional stents, peripheral DCBs offer advantages including no foreign body residue post-procedure, lower risk of inflammation, and better long-term prognosis.

GlaxoSmithKline’s (GSK) long-acting FGF21 analog, efimosfermin alfa, has received IND acceptance from China’s Center for Drug Evaluation (CDE), marking a major advancement in MASH therapy with once-monthly dosing. Engineered to overcome the short half-life of native FGF21, efimosfermin alfa demonstrates a triple mechanism—reducing liver fat, combating inflammation, and reversing fibrosis. Phase II data published in The Lancet showed that after 24 weeks, 68% of patients achieved MASH resolution without fibrosis worsening, 89% had ≥30% liver fat reduction, and 32% reached full liver fat normalization. The drug’s efficacy is independent of GLP-1 background therapy. Acquired by GSK for up to $2 billion, efimosfermin alfa is now advancing into global Phase III trials (ZENITH-1/2) with over 1,250 planned enrollments, offering new hope for China’s estimated 200–300 million NAFLD patients, 10–20% of whom may progress to MASH.